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Abstract
Background: The mitogen activated protein kinase (MAPK) pathways are known to be deregulated in many
human malignancies. Phosphopeptide identification of protein-kinases and site determination are major challenges
in biomedical mass spectrometry (MS). P38 and HuR protein kinases have been reported extensively in the general
principles of signalling pathways modulated by phosphorylation, mainly by molecular biology and western blotting
techniques. Thus, although it has been demonstrated they are phosphorylated in different stress/stimuli conditions,
the phosphopeptides and specific amino acids in which the phosphate groups are located in those protein kinases
have not been shown completely.
Methods: We have combined different resins: (a) IMAC (Immobilized Metal Affinity Capture), (b) TiO2 (Titanium
dioxide) and (c) SIMAC (Sequential Elution from IMAC) to isolate phosphopeptides from p38 and HuR protein
kinases in vitro.
Different phosphopeptide MS strategies were carried out by the LTQ ion Trap mass spectrometer (Thermo): (a)
Multistage activation (MSA) and (b) Neutral loss MS3 (DDNLMS3).
In addition, Molecular Dynamics (MD) bioinformatic simulation has been applied in order to simulate, over a period
of time, the effects of the presence of the extra phosphate group (and the associated negative charge) in the
overall structure and behaviour of the protein HuR.
This study is supported by the Declaration of Helsinki and subsequent ethical guidelines.
Results: The combination of these techniques allowed for:
(1) The identification of 6 unknown phosphopeptides of these protein kinases. (2) Amino acid site assignments of
the phosphate groups from each identified phosphopeptide, including manual validation by inspection of all the
spectra. (3) The analyses of the phosphopeptides discovered were carried out in four triplicate experiments to
avoid false positives getting high reproducibility in all the isolated phosphopeptides recovered from both protein
kinases. (4) Computer simulation using MD techniques allowed us to get functional models of both structure and
interactions of the previously mentioned phosphorylated kinases and the differences between their phosphorylated
and un-phosphorylated forms.
Conclusion: Many research studies are necessary to unfold the whole signalling network (human proteome),
which is so important to advance in clinical research, especially in the cases of malignant diseases.
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As with other MAPK pathways, the p38 signalling cascade
involves sequential activation of MAPK kinase kinases
(MAP3Ks) and MAPK kinases (MKKs) including MKK3,
MKK4, and MKK6, which directly activate p38 through
phosphorylation in a cell-type- and stimulus-dependent
manner [1,2]. Once activated, p38 MAPKs phosphorylate
serine/threonine residues on their substrates, such as tran-
scription factors, cell cycle regulators as well as protein
kinases. The p38 signalling pathway allows cells to inter-
pret a wide range of external signals, such as inflamma-
tion, hyperosmorality, oxidative stress and respond
appropriately by generating a plethora of different biologi-
cal effects [3-14]. HuR has been implicated in processes
such carcinogenesis, proliferation, immune function or
responsiveness to DNA damage [15].
It is of interest to note that numerous HuR-regulated
mRNAs encode proteins responsible for implementing
five major cancer traits:
(a) Promote cell proliferation (p27, cyclin D, Cyclin E1
or EGF)
(b) Increase cell survival (SIRT1, Mdm2 or p21)
(c) Elevate local angiogenesis (VEGF, Cox-2 or HIF-
1alpha)
(d) Invasion and metastasis (Snail, MMP-9, or uPA)
(e) Evasion of immune recognition (TGF-beta).
Moreover, HuR was broadly elevated in cancer tissue
compared to the corresponding non-cancer tissues. It
has been widely reported that in the general principles
of signalling pathways p38 and HuR kinases are modu-
l a t e db yp h o s p h o r y l a t i o n ,m a i n l yb yw e s t e r nb l o t t i n g
techniques. The phosphopeptides and the specific amino
acids in which the phosphate groups are located in
these low expressed proteins have not been completely
shown as yet [16-22].
The analysis of the spatial and temporal aspects of pro-
tein phosphorylation is of great interest for the discovery
of functions of specific biological processes. An extensive
mass spectrometry-based mapping of the phosphopro-
teome progresses and computational analysis of phos-
phorylation has been carried out. Phosphorylation-
dependent signalling becomes increasingly important for
clinical research and requires improvements for each dif-
ferent sample. In addition, the linear sequence motifs
that surround phosphorylated residues have been suc-
cessfully used to characterize kinase-substrate specificity.
To complement phosphoproteomic research, bioinfor-
matics offers a range of methods to analyze and to simu-
late structural properties of the studied phosphoproteins.
Both unphosphorylated and phosphorylated states of a
residue can be generated “in silico” and included in the
appropriate 3D protein context. After this initial model-
ling, Molecular Dynamics (MD) techniques can be
applied in order to simulate, over a period of time, the
effects of the presence of the extra phosphate group (and
the associated negative charge) in the overall structure
and behaviour of the protein [23-25].
We describe the successful strategy (also used by
other scientists [26-28]) for the discovery of 6 unknown
phosphorylated peptides from p38 and HuR kinases.
Our data comes from advances in MS strategies coupled
to different resins (IMAC, TiO2 and SIMAC) that we
have applied, coupled to bioinformatics tools (MD simu-
lation). The specific peptides discovered, which are
phosphorylated in p38 and HuR protein kinases, are
provided. In addition, the specific amino acid assign-
ments of the phosphate groups from the identified phos-
phopeptides are also presented. Unknown phospho-sites
from these kinases in vitro have been discovered for the
first time. Our data is supported by previous scientific
studies related to these protein phosphorylated kinases.
It has have been reported that p38 and HuR kinases are
phosphorylated mainly by western blotting techniques
although not showing all amino acids in which the phos-
phate groups are located. It should be pointed out that the
phosphate groups can vary according to the conditions of
the sample analysis (see references of p38 and HuR pre-
viously mentioned [16-22]). In this study, MSA (multistage
activation) compared to DDNLMS3 (neutral loss MS3)
gave more information for the suite of phosphopeptides
studied when using SIMAC coupled to the ion Trap mass
spectrometer. Using bioinformatics MD simulations we
have proposed functional variations in both structure and
interactions of the previously mentioned phosphorylated-
kinases comparing the phosphorylated and un-phosphory-
lated forms previously described in vitro. Finally, we point
out possible developments or alternatives and complemen-
tary tools with the intention of providing the community
with improved and additional phosphorylation studies of
cellular signalling networks, this being such an important
issue owing to the fact that if we had complete knowledge
of the signalling-networks, many malignant diseases could
be more fully understood and thus facilitate drug develop-
ment for different pathologies. This article also aims to
improve the knowledge of p38 and HuR protein kinases
by identifying and validating new phosphopetides in vitro,
with the knowledge that this is essential to advance in the
knowledge of signalling networks (human proteome).
These and many other advances will help clinical research
investigations, especially in relation to human malignant
diseases.
Materials and methods
Statement of ethical approval
This study was conducted in compliance with the inter-
national “Declaration of Helsinki.” An informed consent
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Ethical Committee of Carlos III Hospital of Health was
obtained. This study adhered to the tenets of the
Declaration of Helsinki. (http://www.wma.net/e/policy/
b3.htm). (Declaration of Helsinki (1964), Belmont (1978)
and agreement of Oviedo (1997) - the basic principles
for human and biological samples research studies -)
http://www.isciii.es/htdocs/index.jsp).(http://www.
madrid.org/cs/Satellite?pagename=HospialCarlosIII,
http://www.cnio.es “working links”)
Purification and Kinase assay
Recombinant glutathione S-transferase (GST) fusion pro-
teins were expressed in Escherichia coli BL21 (DE3) and
purified using standard protocols. p38beta was activated
with MalE-MKK6DD (5:1 ratio) in 50 mM Tris-HCl, pH
7.5, 10 mM MgCl2, 2 mM DTT pH 7.5 and 200 uM ATP
for 1 hour at 30°C. Kinase assay were carried out in a buf-
fer A (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2,2μM
microcystin, 50 mM NaF, and 10 μM ATP) supplemen-
ted with Phosphatase inhibitor cocktail 1 (P2850, 1:100)
and Phosphatase inhibitor cocktail 2 (P5726, 1:100) from
SIGMA, containing 12 μg of HuR and 500 ng of activated
p38 for 30 min at 30°C.
Protein digestion in solution
Proteins (10 μg) were subjected to digestion procedure fol-
lowing the protocol described by Zhao and co-workers
with slight variations [29]. Digestion with Lysyl Endopepti-
dase: the reduced and alkylated sample was incubated at
room temperature for 3 h with 1 μg of lysyl endopepti-
dase/50 μg protein (WAKO). Digestion with Trypsin: the
lysyl endopeptidase-digested sample was diluted with 50
mM NH4HCO3 (Sigma) to make a 5 times dilution of
urea, since trypsin is not fully active at high concentrations
of urea. One microgram of modified trypsin (Promega)
was added per 50 μg of lysyl endopeptidase-digested pro-
tein and the sample was incubated at room temperature
for 16-24 h. The digests were evaporated to about 20 μL
in a SpeedVac centrifuge and subsequently 5 μl were used
for TiO2,5μl for IMAC and 5 μl for SIMAC phosphopep-
tide enrichments.
Dioxide Titanium phosphoenrichment (TiO2)
Titanium dioxide-microcolumns with a length of ~2 mm
were packed in GELoader tips. A small plug of C8 mate-
rial was stamped out of a 3M Empore C8 extraction disk
using an HPLC syringe needle and placed at the con-
stricted end of the GELoader tip. The C8 disk serves only
as a frit to retain the titanium dioxide beads within the
GELoader tip.
Note that the solvent used for either washing or load-
ing the sample onto the TiO2 microcolumn contains
organic solvent (50-80% CH3CN), which abrogates
adsorption of peptides to the C8 material. The TiO2
beads were suspended in 80% acetonitrile, 0.1% TFA,
and an aliquot of this suspension (depending on the size
of the column) was loaded onto the GELoader tip. Gen-
t l ea i rp r e s s u r ec r e a t e db yap l a s t i cs y r i n g ew a su s e dt o
pack the column as described previously. The bound
peptides were eluted using 3 μl of NH4OH, pH 10.5. An
additional elution step using 0.5 μL of 30% acetonitrile
was added to elute peptides, which had remained bound
to the C8 membrane plug. The eluents were pooled and
acidified using 100% formic acid prior to the desalting
step and desalted using Poros-R3 coupled to C18-Disks
microcolumns prior to MS analysis [30,31].
Immobilized Metal Affinity Capture (IMAC)
phosphoenrichment
Purification of phosphorylated peptides was performed
according to Nuhse and co-workers [32] and Lee and co-
workers with minor changes [33]. Briefly 10 μlo fi r o n -
coated PHOS-selectTM metal chelate beads (Sigma) were
washed twice in 100 μl of washing/loading solution
(0.25 M acetic acid, 30% acetonitrile) and resuspended in
40 μl of washing/loading solution. An aliquot of this solu-
tion (20 μl) was incubated with the peptide solution in a
total volume of 40 μl of washing/loading solution for
30 min with constant rotating. After incubation, the solu-
tion was loaded onto a constricted GELoader tip, and gen-
tle air pressure was used to pack the beads. Subsequently
the beads were washed extensively with the washing/load-
ing solution. The bound peptides were eluted using 3 μlo f
NH4OH, pH 10.5, and desalted using Poros R3 coupled to
C18-Disks microcolumn prior to MS analysis.
Sequential Elution from IMAC (SIMAC)
phosphoenrichment
For each experiment 10 μl of iron-coated PHOS-selectTM
metal chelate beads IMAC (Sigma) were used. The beads
were washed twice in loading buffer (0.1% TFA, 50% acet-
onitrile) as described previously [34]. The beads were
incubated with 30 μl of loading buffer and 4 μg of peptide
mixture (tryptic digest). The beads were shaken in a Ther-
momixer (Eppendorf) for 30 min at 20°C. After incuba-
tion, the beads were packed in the constricted end of a
200 μl GELoader tip (Alpha Laboratories) by application
of air pressure forming an IMAC microcolumn. The
IMAC flow-through was collected in an Eppendorf tube
for further analysis by TiO2 chromatography (see below).
The IMAC column was washed using 20 μl of loading buf-
fer, which was pooled with the IMAC flow-through. The
putative monophosphorylated peptides and contaminating
non-phosphorylated peptides were eluted from the IMAC
column using 10 μl of 1% TFA, 20% acetonitrile, and the
possible multiple phosphorylated peptides were subse-
quently eluted from the same IMAC microcolumn using
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solution (Merck) in 490 μl of ultra-high quality water).
The IMAC flow-through and the IMAC eluents were
dried by lyophilization. Titanium Dioxide (TiO2) Chroma-
tography after lyophilization, the pooled flow-through and
wash from the IMAC microcolumn was enriched for
phosphopeptides using TiO2 chromatography. For the
complex mixture of the putative monophosphorylated
peptide fraction (1% TFA) was also subjected to TiO2
chromatography as described below. A TiO2 microcolumn
was prepared by stamping out a small plug of C8 material
from a 3M EmporeTM C8 extraction disk (3M Bioanalyti-
cal Technologies) and placing the plug in the constricted
end of a P10 tip (Eppendorff). The TiO2 beads (suspended
in 100% acetonitrile) were packed in the P10 tip where the
C8 material prevented the beads from leaking. The TiO2
microcolumn was packed by the application of air pres-
sure. Buffers used for loading or washing of the microcol-
umn contained 80% acetonitrile to prevent non-specific
binding to the C8 membrane and the TiO2 beads. The lyo-
philized sample was resuspended in 2 μl of 4 M urea and 3
μl of 1% SDS and diluted five times in loading buffer (1 M
glycolic acid (Fluka) in 80% acetonitrile, 5% TFA) and
loaded onto a TiO2 microcolumn of 5 mm [35]. The TiO2
microcolumn was washed with 5 μl of loading buffer and
subsequently with 30 μl of wash buffer (80% acetonitrile,
5% TFA). The phosphopeptides bound to the TiO2 micro-
columns were eluted using 50 μl of ammonium water (pH
11.3) followed by elution using 0.5 μlo f3 0 %a c e t o n i t r i l e
to elute phosphopeptide bound to the C8 disk. The eluent
was acidified by adding 5 μl of 100% formic acid prior to
the desalting step.
Desalting the isolated phosphopetides by
chromatography reversed phase (RP) using POROs R3
coupled to C18 Disks, prior to MALDI and ESI Mass
Spectrometry analysis
Poros Oligo R3 reversed phase material was from PerSep-
tive Biosystems (Framingham, MA). GELoader tips were
from Eppendorf (Eppendorf, Hamburg, Germany) and
Alpha Laboratories (Hampshire, UK). Orthophosphoric
acid (85%, v/v) was from J. T. Baker Inc. Ammonia solu-
tion (25%) was from Merck. 3M Empore C8 disk was
from 3M Bioanalytical Technologies (St. Paul, MN). All
reagents used in the experiments were sequence grade,
and the water was from a Milli-Q system (Millipore, Bed-
ford, MA). The Poros Oligo R3 reversed phase resin (Per-
Septive Biosystems) was dissolved in 70% acetonitrile.
The R3 beads were loaded onto constricted GELoader
tips, and gentle air pressure was used to pack the beads
to obtain R3 microcolumns of 2 mm. Each acidified sam-
ple was loaded onto a R3 microcolumn. The R3 micro-
columns were subsequently washed with 30 μlo f0 . 1 %
TFA, and the phosphopeptides were eluted directly onto
the MALDI target using 0.5 μlo f2 0μg/μl DHB (Fluka),
50% acetonitrile (ACN), 1% phosphoric acid. MALDI-MS
analysis was just carried out in order to check there were
sufficient eluted peptides to be analyzed by LC-ES-MS,
after the microcolumns applied for the isolation, cleaning
and concentration of putative phosphorylated peptides.
For LC-ESI/MSMS analysis of the phosphorylated pep-
tides originating from the sample, the phosphopeptides
were desalted in a similar way; however, the phosphory-
l a t e dp e p t i d e sw e r ee l u t e df r o mt h eP o r o sR 3c o l u m n
coupled to C18 using 30 μl of 70% acetonitrile, 0.1% TFA
followed by lyophilization. The phosphopeptides were
subsequently resuspended in 0.5 μl of 100% formic acid
and 10 μl of Buffer A (0.1% formic acid, and 5% ACN)
prior to LC-ESI/MS
n analysis (see references previously
mentioned [30,31,35]).
Nano-LC-ESI-MSMS analysis using the LTQ ion Trap mass
spectrometer
The nano-LC-MS experiments were performed using a
LTQ ion Trap mass spectrometer (Thermo Electron,
Bremen, Germany). The sample (5 μl) was applied onto an
EASY nano-LC system following protocols from Thermo
Company and Protein Research Group of Odense Univer-
sity courtesy. Each elute was then entered into a C18
reverse phase column (100 μm i.d., 10 cm long, 5 μmr e s i n
from Michrom Bioresources, Auburn, CA). The peptide
mixtures were eluted with a 0-40% gradient (Buffer A,
0.1% formic acid, and 5% ACN; Buffer B, 0.1% formic acid
and 95% ACN) over 180 min and were then online
detected in LTQ ion Trap- mass spectrometer using a
data-dependent TOP6 method. The general mass spectro-
metric conditions were: spray voltage, 1.85 kV; no sheath
and auxiliary gas flow; ion transfer tube temperature,
1900C; 35% normalized collision energy using for MS/MS
(MS2). Ion selection thresholds were: 500 counts for MS2.
An activation q = 0.25 and activation time of 30 ms were
applied in MS2 acquisitions. The mass spectrometer was
operated in positive ion mode and a data-dependent auto-
matic switch was employed between MS and MS/MS
acquisition modes. For each cycle, one full MS scan in the
LTQ ion Trap followed by ten MS2 in the LTQ at 5000
on the six most intense ions. Selected ions were excluded
from further selection for 90 s. Maximum ion accumula-
tion times were 1000 ms for full MS scans and 120 ms for
MS2 scans. For the pseudo- MS3 method or Multi Stage
Activation (MSA), an MSA was triggered if in the MS2 a
neutral loss peak at -49, -32.7 or -24.5 Da was observed
and that peak was one of the five most intense ions of the
MS2 spectrum. To improve the fragmentation of phos-
phopeptides, multi-stage activation (MSA) in the Xcalibur
software was enabled for each MS/MS spectrum. When a
neutral loss of 97.97, 48.99, or 32.66 Thomson (Th) was
detected, the MSA was applied to further fragment the
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NanoMate
® 100 was mounted to the Finnigan LTQ, and 5
μL (like for MSA) samples were infused at a rate of
approximately 100 nL/min. Mass Spectrometer: Finnigan
LTQ ion Trap. Ionization Mode: Nano-electrospray, Ion
Polarity: Positive, Spray Voltage: 1.55 kV, Spray Pressure:
0.2 psi., Capillary Temperature: 150°C, Normalized Colli-
sion Energies: 20-25% for MSn., Maximum Scan Time: 50
ms., Number of Micro Scans Summed for Each Scan: 2-3.
Neutral loss MS3 experiment activated for the loss of 98,
49 and 32.7 (singly, doubly and triply charged phospho-
peptides). [Mascot searches (http://proteomicsresource.
washington.edu/mascot/search_form_select.html) were
carried out by “in-Mascot-house server of Centro Nacional
de Investigaciones Oncológicas CNIO, http://www.cnio.
es”].
Database searching using an in-house MASCOT server
and the validation of the identified phosphopeptides
The Mascot generic format file was produced by the fol-
lowing process: the utilities provided by Thermo Elec-
tron and Bioworks first converted Xcalibur binary
(RAW) files into peak list (DTA) files, then the pro-
grams of merge.pl and merge.bat provided by MASCOT
public web merged all DTA files into a Mascot generic
format file.
For peptide or protein identification, all the raw data
files were processed using BioWorks 3.3.1 (Thermo Fin-
nigan, San Jose, CA) and the derived peak list was
searched using the Mascot search engine (Matrix
Science, London, UK) against a real and false human IPI
protein database (V3.49), respectively. The following
search criteria were employed: full tryptic specificity was
required; two missed cleavages were allowed; carbamido-
methylation (Cys) was set as fixed modification, whereas
oxidation (Met), N-acetilation (protein), phosphorylation
(STY), and intact phosphorylation (STY) were considered
as variable modifications. Initial mass deviation of pre-
cursor ion and fragment ions was allowed up to 10 ppm
and 0.5 Da, respectively. A peptide identified by Mascot
was accepted if it had a peptide score above 20 in all the
experiments performed. In addition, each phosphopep-
tide spectrum assignment was manually validated. All of
the potential phosphopeptides were confirmed by manual
interpretation of MS/MS and MSA ion spectra using the
criteria described by Mann and Jensen [36], Gruhler and
co-workers [37], and Thingholm and co-workers [38].
Bioinformatics modelling and molecular dynamics
simulations
Crystal structure of MAP kinase p38beta protein and 3D
coordinates of the quaternary structure of the first RNA
recognition motif of human HuR protein were obtained
from the Protein Data Bank (PDB <http://www.pdb.org>
codes: 3GC8 - and 3HI9 -[39]- [40]-, respectively). As the
published structure of HuR dimmer (dimmer) [40]
showed a gap between residues 53 and 60 of the first
monomer (chain B in 3HI9 structure), the coordinates
for this external loop were completed by standard homol-
ogy modelling procedures using the second monomer
(chain D of 3HI9) as template. Model was built using
SWISS-MODEL server facilities at http://swissmodel.
expasy.org//SWISS-MODEL.html, and its structural
quality was checked using the analysis programs provided
by the same server (Anolea/Gromos/QMEAN4) [41-43].
Molecular dynamics (MD) simulations of the behaviour
of human HuR dimmer (dimmer) in both unphosphory-
lated and phosphorylated states of Ser-48 residue were
performed using the PMEMD module of AMBER10 and
the parm-99 parameter set [44]. Two independent MD
simulations were carried out: one for the modelled non-
phosphorylated protein and a second one for the same
system but containing a phosphorylated Ser residue in
position 48. To simulate phospho-Ser, a tailored-made
“prep” file for AMBER was used, as described in Men-
dieta and co-workers (2005) [45]. In order to neutralize
the system’s electrostatic charge, Cl
- counterions were
placed in a shell around the system using a grid of cou-
lombic potentials. The electrostatically neutralized com-
plexes were then embedded in a truncated octahedron
solvation box, keeping a distance of 12 Å between the
limits of the box and the closest atom of the solute. Both
counterions and solvent were added using the LEAP
module of AMBER. Initial relaxation of each complex
was completed by performing 10000 steps of energy
minimization with a cut-off of 10.0 Å. Before starting the
MD simulation, the temperature was raised from 0 to
298K, in a 200 ps continuous heating phase. During this
stage, velocities were reassigned at each new temperature
according to the Maxwell-Boltzmann distribution, and
positions of the Ca trace of the solute were constrained
with a force constant of 500 kcal mol
-1rad
-2 to impede a
spurious disorganization of the structure during the heat-
ing of the system. During the last 100 ps of the equilibra-
tion phase of the MD, the force constant was reduced
stepwise down to 0 for all constrained atoms. Final tra-
jectory length of both MD simulation processes were of
10 ns over the complete systems. During the full trajec-
tory, SHAKE algorithm was used to constrain hydrogen
bonds to their equilibrium values with an integration
time step of 2 fs, updating the list of non-bonded pairs
every 25 steps and saving coordinated every 2 ps. Peri-
odic boundary conditions were applied. Electrostatic
interactions were represented using the smooth particle
mesh Ewald method with a grid spacing of about 1 Å.
Final analysis of the trajectories was performed using the
CARNAL module of AMBER10. The proteomics coupled
to bioinformatics pipe-line strategy used for this research
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(Figure 1).
Results
Identified phosphopeptides
(a) The aim of this study was to establish, as a routine
path, a method for identification and characterization of
individual phosphorylated kinases p38 and HuR in vitro
using: TiO2, IMAC, SIMAC coupled to MSA and MS3NL
on the LTQ ion Trap mass spectrometer (Thermo). Purifi-
cation and fusion proteins were expressed in Escherichia
coli. The kinase assay was carried out incubating with dif-
ferent types of protein phosphatase inhibitors in order to
increase the levels of protein-kinases phosphorylation
prior to the analysis. In fact, sodium pervanadate, a tyro-
sine phosphatase inhibitor, coupled to a combination of
two phosphatase inhibitor cocktails from Sigma (one cock-
tail containing serine/threonine phosphatase inhibitors
and one containing tyrosine phosphatase inhibitors) was
also used. Protein kinases were digested with lysyl endo-
peptidase and trypsin and subsequently enriched for phos-
phorylated peptides using TiO2,I M A Ca n dS I M A C
Figure 1 The work flow for proteomic and bioinformatics PTM analysis is illustrated. [A] Proteins isolated from kinase assays are in-
solution digested into peptides using the proteases Lysyl Endopeptidase and Trypsin. The peptides containing specific post-translational
modifications (phosphorylation) are enriched using different resins. Non-modified peptides are used to identify proteins. [B] Purified peptides are
separated on a miniaturized reverse phase chromatography column with an organic solvent gradient. Peptides eluting from the column are
ionized by electrospray at the tip of the column, directly in front of the mass spectrometer. [C] The electrosprayed ions are transferred into the
vacuum of the mass spectrometer. In the mass spectrometer (MS mode) all ions are moved to the mass analyzer (ion Trap), where they are
measured at high resolution. The mass analyser then selects a particular peptide ion and fragments it in a collision cell. For modified peptides,
the peptide mass will be shifted by the mass of the modification, as will all fragments containing the modification, allowing the unambiguous
placement of the PTM on the sequence. [D] The mass and lists of fragment masses for each peptide are scanned against protein sequence
databases, resulting in a list of identified peptides and proteins. The lists of proteins and their peptides are the basis for bioinformatics analysis,
in order to acknowledge improvements.
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desalted, cleaned and analyzed by nano-LC ESI-MS/MS
using a Thermo LTQ ion Trap MSMS instrument. All
experiments were performed in triplicate. The LC-MS/MS
experiments and Mascot database searching resulted in
overall significant peptide hits. All the peptides were deter-
mined with a mass error of less than 5.5 ppm. A total of 6
phosphopeptides were validated by manual evaluation of
the LC-MS/MS data sets obtained from the four tripli-
cated experiments. Of these, 6 were assigned to unique
amino acid phosphorylated sequences resulting in the
identification of 3 unique proteins across all experiments.
(b) The analysis of the 5 μl (~3 μg) of the sample pur-
ified by IMAC and desalted and cleaned by R3/C18 per-
mitted us to obtain 2 unknown phosphorylated peptides
when using MSA on the nano-LC-LTQ ion Trap instru-
ment. Both phosphorylated peptides were manually vali-
dated and correspond to: R.VLVDQTTGLSR.G and R.
SLFSSIGEVESAK.L. Those two phosphopeptides belong
to the HuR RNA binding protein gi/1022961 protein.
The analysis of 5 μl( ~ 3μg )o ft h es a m p l ep u r i f i e db y
TiO2 and desalted and cleaned by R3/C18 permitted us
to obtain 4 unknown phosphorylated peptides when
using MSA on the nano-LC-LTQ instrument.
The four phosphorylated peptides were manually vali-
dated and correspond to: R.VLVDQTTGLSR.G, R.
SLFSSIGEVESAK.L, K.DVEDMFSR.F which belong to
the HuR RNA binding protein gi/1022961 and; another
phosphopeptide: K.DLSSIFR.G which belongs to p38
MAP Kinase gi/1469306 (Table 1).
The analysis of the 5 μl (~3 μg) of the sample purified
by SIMAC and desalted and cleaned by R3/C18 allowed
us to obtain 6 unknown phosphorylated peptides when
using MSA on the nano-LC-LTQ ion Trap instrument.
The six phosphorylated peptides were manually vali-
dated and correspond to: K.DVEDMFSR.F, R.VLVD
QTTGLSR.G, K.DANLYISGLPR.T, R.SLFSSIGEVESAK.
L which belong to HuR RNA binding protein gi/
1022961 and; R.TAVINAASGR.Q which belongs to
Chain B, Structure Of Appbp1-Uba3-nedd8-Mgatp-
Ubc12 (c111a), A Trapped Ubiquitin-Like Protein Acti-
vation Complex gi/126031226, and K.DLSSIFR.G which
belongs to p38 MAP Kinase gi/1469306 (Table 1).
Therefore, when using MSA by the LTQ Ion Trap
instrument, SIMAC (6 phosphopeptides purified, iden-
tified and validated) efficiency is higher than TiO2 (4
phosphopeptides purified and identified) and IMAC (2
phosphopeptides purified, identified and validated) for
these protein-kinases studied. It has been described
that IMAC easily enriches multiple phosphorylated
peptides while TiO2 mono-phosphorylated ones. In
fact, SIMAC has been optimized to get the best effi-
ciency from IMAC and TiO2 and complement both in
just one method (see reference previously mentioned
[34]). This supports our data.
In any case, we recommend that in order to study
kinase phosphorylated protein kinases, combine the
three resins (or ever more phosphoenrichments meth-
ods) in order to purify as many as possible phosphopep-
tides [46]. The reason for this is that each sample needs
to be optimized and tested with different complemen-
tary strategies. The analysis of the 5 μl( ~ 3μg) of the
sample purified by SIMAC and desalted and cleaned by
R3/C18 allowed us to get 5 unknown phosphorylated
peptides when using Data Dependent Neutral Loss MS3
(DDNLMS3) on the nano-LC-LTQ ion Trap instrument.
Table 1 The 3 phosphorylated proteins (HuR, Chain B and p38p) and the 6 phosphopeptides identified and validated
(amino acid sequences below the identified proteins) when using SIMAC coupled to MAS by the LTQ ion Trap mass
spectrometer are shown in this table
Proteins Phosphopeptides
HuR RNA binding protein gi/1022961 DVEDMFSphR (*)
VLVDQTTphGLSR
DANLYSphGLPR (*)
SLFSSIGEVESphAK (*)
Chain B, Structure Of Appbp-1-Uba3-nedd8-Mgatp-Ubc 12 (c111a), A Trapped Ubiquitin-Like Protein Activation Complex
gi/126031226
TphAVINAASGR (*)
P38 MAP Kinase gi/1469306 DLSphSIFR (*)
Around ≥ 3 μg of complex peptides mixture were loaded into SIMAC micro-columns and analyzed by nano-LC-ESI-LTQ ion Trap (Thermo).
In addition when using SIMAC coupled to DDNLMS3 3 proteins were identified: (a) HuR RNA binding protein gi/1022961, (b) P38 MAP Kinase gi/1469306 and (c)
Change B, A Trapped Ubiquitin like-protein activation gi/126031226.
(a) From the phosphorylated protein HuR RNA binding protein gi/1022961, 3 phosphopeptides were isolated and validated (K.DVEDMFSR.F, K.DANLYISGLPR.T,
R.SLFSSIGEVESAK.L).
(b) From the phosphorylated protein p38 MAP Kinase gi/1469306, one phosphopeptide was isolated and validated (K.DLSSIFR.G).
(c) From the phosphorylated protein Change B, A Trapped Ubiquitin like-protein activation gi/126031226, one phosphopeptide was isolated and validated
(R.TAVINAASGR.Q).
[Identified and validated phosphopeptides using SIMAC coupled to DDNLMS3 are distinguished by the symbol (*)]
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Page 7 of 16The five phosphorylated peptides were manually vali-
dated and correspond to: K.DVEDMFSR.F, K.DAN-
LYISGLPR.T, R.SLFSSIGEVESAK.L which belong to
HuR RNA binding protein gi/1022961; K.DLSSIFR.G
which belongs to p38 MAP Kinase gi/1469306 and R.
TAVINAASGR.Q which belongs to Chain B, Structure
Of Appbp1-Uba3-nedd8-Mgatp-Ubc12 (c111a), A
Trapped Ubiquitin-Like Protein Activation Complex gi/
126031226 (Table 1).
(c) SIMAC coupled to MAS and MS3-NL mass spectro-
metry analysis. The preferred approach for analyzing sam-
ples using mass spectrometry is to produce structurally
significant product ions using the process of ion dissocia-
tion. A method commonly known as Data Dependent
Neutral Loss MS3 (DDNLMS3) (developed by Coon and
co-workers [47]) analysis enables selective fragmentation
by isolating a neutral loss ion fragment from an MS/MS
experiment and then subjecting it to further dissociation
[48]. Despite of this, DDNLMS3 did not allow us to get as
efficient results as when using MSA for our protein-
kinases analyses. It is well known that the production of
neutral loss ions in MS/MS, is almost always accompanied
by partial fragmentation of the precursor ion and these
diagnostic fragment ions are subsequently lost when the
neutral loss ions are isolated for MS3. Multistage activa-
tion (or pseudo MS3) allowed us to get spectra that were
the combination of MS/MS and MS3 fragmentation and
thus retaining the informative fragments from the precur-
sor ion more efficiently. This is due to the fact that MSA
produced more structurally informative ions by eliminat-
ing the ion isolation step between MS/MS and MS3 for
the study of phosphorylated protein kinases p38 and HuR
in vitro. We observed that - in this research study related
to the previously phosphorylated proteins after in vitro
kinase reaction- multistage activation was a faster route to
a more information- rich spectra since the ion-trap does
not require refilling for the MS3 scan, as with the tradi-
tional neutral loss experiment (DDNLMS3). We con-
cluded during the first tests-analyses of the protein kinases
in vitro,t h a tw h e nc o m p a r e dt oD D N L M S 3 ,m u l t i s t a g e
activation generated spectra with increased signal intensity
and a greater number of structurally diagnostic ions for
phosphorylated peptides. Thus we chose MSA as a routine
path for this kind of analysis (p38 and HuR phosphory-
lated kinases in vitro). Further benefits of using multistage
activation are demonstrated in other studies of phospho-
peptides, including large scale analysis [49]. The informa-
tion-rich spectra generated using multistage activation
were particularly important for these compounds because
there is often a significant loss of sequence informative
fragment ions generated in MS/MS. For this study, more
ions were identified with multistage activation than with
MS/MS or MS3 in the DDNLMS3 method. In addition,
the signal intensities were generally higher with multistage
activation compared to MS/MS or MS3 of DDNLMS3
method. In fact, multistage activation resulted in more
information for the suite of phosphopeptides studied
(Table 1) (see an example of the spectrum of an identified
phosphorylated peptide when using SIMAC coupled to
MSA in the LTQ ion Trap mass spectrometer and Mascot,
Figure 2).
Nevertheless, it must be pointed out that Jiang and co-
workers developed a specific classification filtering strategy
for their studies (using different samples) which signifi-
cantly improved the coverage of the phosphoproteome
analysis when using NLMS3 (see reference previously
mentioned [48]). In fact, Jiang and co-workers obtained a
higher coverage of the phosphopeptide identifications
when processing and filtering specific methods which they
developed for the spectra from NLMS3, compared with
MS2 and MSA strategies. In relation to this, we should say
that just one more phosphopeptide was identified and vali-
d a t e dw h e nw eu s e dS I M A Cc o u p l e dt oM S A( n e w6
identified phoshopeptides) compared to when we coupled
SIMAC to DDNLMS3 (5 new identified phosphopeptides).
In addition, those 5 new phosphorylated peptides identi-
fied and their phospho-site assignments in each specific
amino acid are the same ones following both strategies
(see Figure 3 and Table 1). Moreover, the 6 new phospho-
peptides and phospho-site assignments showed high
reproducibility in all cases during the four triplicate
experiments we carried out.
All our MS analyses were carried out by CID. We
hypothesize that combining CID with ETD or ECD frag-
mentation, it is probable that more and/or complementary
data would be obtained according to the methodological
study of Navajas and co-workers [50]. ECD occurs only on
the peptide backbone - which is an advantage -, and labile
phosphate groups are left intact on the resulting c- and z-
fragment ions, thus, complementary identification of other
specific phosphorylation sites would be enabled [51,52].
As a result, we recommend using CID to start with, and
would recommend switching to ETD, in the event you
were not able to determine the phosphorylation site, if you
have the possibility of the required instrument [53-57].
The phosphopeptides purified, identified and validated,
including also the site-assignments of the phosphate group
are illustrated in Table 1.
The efficiency and reproducibility of the phosphopep-
tide purification and identification when using ~3 μgo f
protein kinases per each resin and or phosphoenrich-
ment method (SIMAC, TiO2 and IMAC) coupled to R3/
C18 and MSA-LTQ ion Trap mass spectrometer is illu-
strated in Figure 3.
An example of a phospho-site assignment and manual
validation of the phosphorylated peptide (VLVDQ
TTphGLSR) obtained by Mascot analysis is illustrated in
Figure 2.
López et al. Journal of Clinical Bioinformatics 2011, 1:16
http://www.jclinbioinformatics.com/content/1/1/16
Page 8 of 16Figure 2 Phospho-site assignment & manual validation of the phosphorylated peptide VLVDQTTphGLSR obtained by Mascot analysis.
The monoisotopic mass of neutral peptide Mr (calc) resulted was 1267.6173. Fixed modifications chosen were: Carbamidomethyl (C), while for
variable modifications T7: Phospho (ST), with neutral losses 97.9769 (shown in table) was selected. The y5 ion and b7 are those which allowed
identification of the treonine (5) as phosphorylated (ph) amino acid (T in red colour). In addition the phosphate fingerprint of the neutral loss
(NL) from the parent ion is also a positive signal of phosphorylation. Six b ions and 8 y ions were continuously matched respectively.
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Page 9 of 16Bioinformatic modelling and molecular dynamics
simulations
To study the potential functional effect of serine phos-
phorylation in the above indicated sequence locations, 3D
structural models for the phosphorylated state of both
MAP kinase p38beta (p38B) and HuR were generated
using bioinformatics procedures. As shown in figure 4,
phosphorylated Ser-279 of p38B is located in a loop placed
on the external surface of the protein structure, far away
from the active site of the kinase. It is conceivable that the
phosphorylation of this residue does not affect p38B struc-
ture stability or folding, but external contacts to accompa-
nying proteins, modulate the nature of the putative
interaction (see reference previously mentioned [39]).
I nt h ec a s eo fH u R ,o n l yo n eo ft h ef o u rp h o s p h o r y -
lated residues found (Ser-48) fall into a structure
Figure 3 The efficiency and reproducibility of the phosphopeptide purification and identification when using ~3 μg of protein kinases
per each resin and/or phosphoenrichment method (SIMAC, TiO2 and IMAC) coupled to R3/C18 and MSA-LTQ ion Trap mass
spectrometer is illustrated. [A] Four triplicate experiments were carried out in order to identify the phosphopeptides. The phospho-site
identifications were carried out from pooled and non-pooled assays (inter- and intra-assays) confirming a high reproducibility. The 6
phosphorylated peptides identified were isolated and validated in the four triplicate analyses, not only by Mascot (at least 4 continuously -y and
-b ions matched)but also by manual inspection of all the spectra. SIMAC allowed the purification of 3 phosphorylated proteins: HuR RNA
binding, p38 MAP Kinase and Trapped Ubiquitin-Like Protein Activation Complex, and 6 phosphorylated peptides related to those previously
mentioned proteins. TiO2 and IMAC allowed the isolation of 2 phoshorylated proteins: HuR RNA binding and p38 MAP Kinase, and 1
phosphopeptide related to the protein kinase HuR RNA binding. [B] SIMAC coupled to MSA allowed the identification of one more
phosphopeptide compared to SIMAC coupled to DDNLMS3. Nevertheless, both strategies (SIMAC coupled to MSA and SIMAC coupled to
DDNLMS3) allowed the identification of the same number of phosphorylated proteins (3). [C] and [D] Three phosphorylated proteins and six
phosphopeptides were identified when using SIMAC coupled to MSA. From those three phosphoproteins identified, six phosphopeptides were
identified: (a) TiO2 coupled to MSA allowed the identification of two equal/same phosphorylated proteins and four equal/same phosphopeptides
as SIMAC and (b) IMAC allowed the identification of one equal/same protein and two equal/same phosphopeptides. Thus, SIMAC is more
efficient than the other tested resins for this study, while TiO2 and IMAC corroborate the reproducibility of the phosphorylated proteins and
phosphopeptides identified.
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Page 10 of 16domain of the protein previously crystallized: the dim-
merized first RNA recognition motif (see reference pre-
viously mentioned [40]). Thus, only the putative
structural effect of the phosphorylated and non-phos-
phorylated state of Ser-48 could be analyzed through
structural bioinformatic tools including Molecular
Dynamics (MD) simulation.
As shown in figure 5A, Ser-48 is located in the dim-
merization surface, surrounded by residues Glu-47 and
Lys-50 that form a pair of saline bonds potentially impli-
cated in the stabilization of the dimmer. To test the effect
of the presence of a phosphorylated Ser in the mainte-
nance of the quaternary structure, two unrestricted MD
computer simulations were performed in presence or
absence of a phosphorylated Ser in position 48, as indi-
cated under “Materials and Methods”. Results obtained
after 10ns of MD showed that, in the case of the unpho-
sphorylated dimmer structure (non-phosphorylated Ser-
48), both monomers experimented a significant displace-
ment from their initial relative positions, resulting in a
complete disorganization of the quaternary structure
(Figure 5B -left-). Measurement of root mean square
deviation (RMSD) values of the monomers and the dim-
mer, as well as the distances between the C atoms of the
contact residues (Glu47A-Lys50B, Ser48A-Ser48B and
Lys50A-Glu48B) indicated a clear and irreversible displa-
cement from the initial values during the first steps of
the MD simulation (Figure 5C, upper plots). In contrast,
w h e nt h es a m eM Ds i m u l a t i o nw a sp e r f o r m e di np r e -
sence of a phosphorylated Ser in position 48 of both
monomers, a clear stabilization of the dimmerized struc-
ture was obtained, showing no displacement from their
initial position (Figure 5B -right-) and exhibiting constant
values of RMSD values and invariable RMSD values and
distances between contact residues (Figure 5C, lower
plots).
Figure 4 Location of phosphorylated Ser-279 in the protein structure of human MAP kinase p38beta (p38B).Am o d e lf o r
phosphorylated serine was located in the structural position of residue Ser-279 in the 3D crystallographic coordinates of p38B (Protein Data
Bank code: 3GC8). Position of the ATP binding site is indicated. Plot was generated using PyMOL (DeLano Scientific, San Carlos, CA).
López et al. Journal of Clinical Bioinformatics 2011, 1:16
http://www.jclinbioinformatics.com/content/1/1/16
Page 11 of 16These results suggest that the phosphorylation of Ser48
in the first protein RNA recognition motif of HuR has
potentially a stabilizing effect, exerting a regulatory role on
the biological function of protein by regulating the mainte-
nance of the dimmerized quaternary state, a requirement
of the complex prior to RNA binding activity [58].
Discussion
Reversible protein phosphorylation plays an important
role in the regulation of many different processes, such
as cell growth, differentiation, migration, metabolism,
and apoptosis. Identification of differentially phosphory-
lated proteins by means of phospho-proteomic analysis
Figure 5 Effect of the phosphorylation of Ser-48 in the stability of the dimmer structure of the first RNA recognition motif of HuR. [A]
Crystal structure of HuR dimmer (Protein Data Bank code: 3HI9, chains B and D) indicating the position of Ser-48, Glu-47 and Lys-50 in the
dimmerization surface. [B] Relative spatial position of the two HuR monomers after 10ns of unrestricted Molecular Dynamics (MD) simulation of
both non-phosphorylated (red structure, left) and phosphorylated (green structure, right) states of Ser-48. Position of initial dimmer structure,
prior to the MD simulation, is included for comparison (in gray). Note the large displacement of the non-phosphorylated state in contrast to the
stability exhibited by the dimmer in presence of phosphoSer48. Respective positions of Ser-48 and phosphoSer-48 are indicated. [C] Left: RMSD
values measured for HuR dimmer (red) monomer A (blue) and monomer B (green) during the 10 ns trajectory of the unrestricted MD simulation
of the dimmer in presence of non-phosphorylated Ser-48 (HUR plot, top panel) or phosphorylated pSer-48 (HURP plot, lower panel). Right:
continuous measurement of Ca Ca distances between residues E47(A)-K50(B) (red), S48(A)-S48(B) (blue) and E47(A)-K50(B) (green), during the
MD trajectory. Distortion of the HuR dimmer in the presence of Ser-48 (HUR plot, top panel) when compared to the phosphorylated state of the
protein (HURP plot, lower panel) is patent in both RMSD and Ca-Ca measurements. Structure plots were generated as in Figure 4.
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Page 12 of 16coupled to bioinformatic tools provides insight into sig-
nal transduction pathways that are activated in response
to, for example, growth factor stimulation or toxicant-
induced apoptosis [59]. Four triplicate experiments were
carried out in order to identify the phosphopeptides of
the protein kinases studied in this article (p38 and HuR).
The phospho-site identifications were carried out from
pooled and non-pooled assays (inter- and intra-assays)
confirming a high reproducibility: the 6 isolated and
identified phosphorylated peptides were validated in the
four triplicate analyses by Mascot (score >20, and at least
4-y and -b ions continuously matched) also including
manually inspection via phosphate-fingerprints of all the
spectra. It should be pointed that some spectra showed a
better resolution than others. Three different resins
(IMAC, TiO2 and SIMAC) were used despite the fact
that it is well known that SIMAC has been developed
and described as a method to purify more phosphopep-
tides for high-throughput analysis giving great efficiency
(see references previously mentioned [34-36]). But it has
also been demonstrated that the analyses of different
phosphorylated proteins when using different resins (e.g.
TiO2,I M A Co rZ r O 2) -including SIMAC- are more effi-
cient in a complementary way for specific samples. This
is due to the fact that the intrinsic characteristic of each
protein (e.g. amino acid composition). In fact, in order to
get as many phosphopeptides as possible from the same
sample, different tests must be carried out [e.g of other
possibilities of phosphoenrichments: Strong cation and
anion exchange (SCX and SAX), Calcium phosphate pre-
cipitation, Hydrophilic interaction chromatography
(HILIC)]. Moreover, phosphoproteomic analysis of
kinases implies more difficulties as they usually are low
expressed proteins with the disadvantage that the un-
phosphorylated form is more abundant than the phos-
phorylated within the sames a m p l et ob ea n a l y z e d .I n
addition, IMAC elutes easily multi-phopshorylated pep-
tides than TiO2 and ZrO2.T i O 2 and ZrO2 have the capa-
city of binding strongly the multiple phosphorylated
peptides, thus both last mentioned resins retain multi-
phosphorylated peptides and do not give -usually- the
chance to elute them. We chose TiO2 for our research
study instead of ZrO2 although they are of similar char-
acteristics, but further experiments using ZrO2 or other
resins or different possibilities of phosphoenrichments
(SCX and/orHILIC for e.g) could surely give complemen-
tary and interesting data for signalling network research
advances. The phosphopeptides found in the analyzed
sample corresponding to p38 MAP kinase protein do not
include the described phosphorylation sites in the T-loop
(pThr-180 and pTyr-182). We hypothesize that the pro-
tein was not phosphorylated in those precise sites in the
original sample, indicating a particular inactive state of
t h ek i n a s ea c t i v i t y[ 6 0 , 6 1 ] .I na d d i t i o n ,w ed e t e c t e d
unphosphorylated peptides after protein digestions by
MS and Mascot analysis. These unphosphorylated pep-
tides were very useful for the assured identification of the
studied protein kinases. During the evaluation of the
data, we found that the peptide scores of phosphopep-
tides assigned by Mascot did not always correlate with
the quality of the spectra, and for this reason, all frag-
mentation spectra were manually verified, in order to
avoid false positives. A peptide was accepted when at
least four consecutive y- and b- ions were assigned to
abundant signals in the fragmentation spectra. If this was
not the case, then the amino acid sequence was inspected
to look for indications of why these y/b-ions were miss-
ing. Peptides lacking a C-terminal arginine or lysine resi-
due, due to a C-terminal position in the particular
protein sequence, were accepted, when at least four con-
secutive b-ions had been assigned in the fragmentation
spectra. Peptides with a C-terminal lysine residue and an
N-terminal arginine residue due to missed cleavage were
also accepted, when at least four consecutive b-ions were
assigned in the fragmentation spectra. In addition, the
spectra were inspected for the presence of proline resi-
dues, which usually give rise to intense signals, suppres-
sing other signals in the spectra. A neutral loss of 98 Th
due to the loss of phosphoric acid resulting from gas-
phase Β-elimination of phosphoserine or phosphothreo-
nine residues together with the presence of dehydroala-
nine or dehydro-2-amino butyric acid or the presence of
intact phosphoserine or phosphothreonine residues in
the sequence were used as indicators of a serine or threo-
nine phosphorylated peptide, respectively. The character-
istic phosphotyrosine immonium ion at 216.05 Th or the
presence of an intact phosphotyrosine residue in the
sequence was used for confirmation of tyrosine phos-
phorylation if it was the case. The analysis by the
LC-nano-ESI-LTQ ion Trap and the manual validation of
the MS/MS and MSA spectra was performed by EL fol-
lowing the rules of Mann and Jensen (see references
[36,57]). (Table 1, Figure 2, Figure 3).
One of the disadvantages of Electron Capture Dissocia-
tion (ECD) is that it has selectivity for disulfide bonds,
due to the high radical affinity of the bond. Further ana-
lysis related to these protein kinases will be carried out as
it preserves the intact information about labile modifica-
tions, which are not observed directly when using CID at
t h es a m et i m ew i t ht h ek n o w l e d g et h a tt h ed r a w b a c ko f
ETD is less sensitive compared to CID, because of lower
ionization efficiency. Thus more complementary data
would be available soon. A third phosphorylated protein
(Trapped ubiquitin-like protein complex gi/126031226)
was isolated and identified during the MS analysis of the
p38 and HuR protein kinases. Apparently, this third
phosphorylated protein seems to be linked to p38 and
HuR kinases. The reason for that could be the kinase
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Page 13 of 16assay. The origin of the Ubiquitin-like protein activation
complex protein needs to be studied in a deep way, as
although p38/MAPK is a fundamental actor for the net-
work connectivity of signalling partners, no data yet
clearly implicate gi/126031226 in these processes or
interactions (see references [53-59])
MD bioinformatics simulations are often good indica-
tors of potential behaviour of protein-protein complexes;
but they are only computational results, but coupled to
experimental proteomics data, they give relevant clues. In
fact, this study suggests that the phosphorylation of
Ser48 in the first protein RNA recognition motif of HuR
has potentially a stabilizing effect (Figure 5), exerting a
regulatory role on the biological function of protein by
regulating the maintenance of the dimmerized quatern-
ary state, a requirement of the complex prior to RNA
binding activity (see reference [58]). In addition, a figure
illustrating the 3D position of phosphorylated Ser-279 in
the structure of human MAP kinase p38beta (Figure 4)
(p38B) indicates clearly that this precise phosphorylation
site is located far from the ATP binding site and also far
from the T-loop, indicating a different role for this resi-
due, which opens a new research door for this relevant
protein kinase [59-61].
Conclusions
Our proteomics studies have demonstrated that there are
6 new phosphopeptides of the protein kinases p38 and
HuR during in vitro assays. This was possible by testing
different resins coupled to different MS strategies to iso-
late and identify phosphopeptides. The identified phos-
phopeptides were manually validated and the phospho-site
assignments were also carried out in order to avoid false
positives. Recently, several signalling studies for clinical
research are ongoing and each sample needs to be tested
by different strategies in order to check which one adapts
better to your goals, the characteristics of the proteins to
be studied, and the possibility of getting complementary
data. The experiments carried out showed excellent repro-
ducibility in the four triplicate experiments for the identifi-
cation and validation of the identified phosphopeptides,
also for the protein identifications of p38 and HuR kinases.
A Trapped ubiquitin-like protein complex gi/126031226
was also isolated and identified containing one phospho-
peptide during this study. The origin of the Ubiquitin-like
activation complex protein needs to be studied in a depth
as although p38/MAPK is a fundamental actor for the net-
work connectivity of signalling partners, no data yet clearly
implicate gi/126031226 in these processes or interactions.
Overall, the combination of SIMAC and MSA resulted
more efficient to isolate and identify phosphopeptides
from p38 and HuR protein kinases. It should be pointed
out that when using other phosphoenrichment alternatives
(SCX and HILIC) coupled to other MS strategies for this
study, we will be able to corroborate even more comple-
mentary data related to the results presented.
Bioinformatic studies, using structural tools, of reversible
phosphorylation in proteins will allow the generation of
useful models for protein-protein contacts at the atomic
level. These models can be used as input for sophisticated
techniques, as molecular dynamics, that offer the possibi-
lity of analyzing the potential effect of the phosphorylation
and de-phosphorylation process of each residue in the glo-
bal structure and behaviour of the protein. In the present
work, the molecular dynamics analysis of the phosphoryla-
tion of Ser-48 in HuR homodimmer offered a suitable
hypothesis of how the phosphorylation state of Ser-48 can
regulate the protein mechanism through controlling the
homodimmerization arrangement of the corresponding
structural domain. Regarding the 3D position of phos-
phorylated Ser-279 in the structure of human MAP kinase
p38, molecular simulation clearly indicates that this pre-
cise phosphorylation locus is located far from the ATP
binding site and also far from the T-loop, indicating a dif-
ferent role for this residue: this could open a new and rele-
vant research door for this important protein kinase,
which has been related as a connectivity-link for different
signalling pathways.
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